12:00 AM
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ixempra ixabepilone: Final Phase II data

Bristol-Myers said that final data from an open-label Phase II trial in 54 previously untreated patients with locally advanced or metastatic pancreatic cancer showed that Ixempra plus Erbitux cetuximab missed the primary endpoint of significantly improving 6-month survival. Specifically, the survival rate at 6 months was 62% with a 95% confidence interval of 49-75%, which did not exclude the pre-specified hurdle of 50%. The 12-month survival rate was 40%. Median...

Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >